Expert Ratings For GeneDx Hldgs
Portfolio Pulse from Benzinga Insights
In the past three months, 6 analysts have released ratings for GeneDx Holdings (NASDAQ:WGS), with a mix of bullish and neutral sentiments. The average 12-month price target has increased significantly to $27.33 from $14.30. Analysts from firms like Goldman Sachs, Craig-Hallum, BTIG, and TD Cowen have raised their price targets, reflecting positive outlooks. Despite strong revenue growth, GeneDx faces challenges with profitability and returns.
July 17, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeneDx Holdings (NASDAQ:WGS) has received a mix of bullish and neutral ratings from analysts over the past three months. The average 12-month price target has risen to $27.33, indicating a positive outlook. However, the company faces challenges with profitability and returns despite strong revenue growth.
The significant increase in the average 12-month price target and the bullish ratings from multiple analysts suggest a positive short-term impact on GeneDx Holdings' stock price. However, the company's challenges with profitability and returns may temper this optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100